scispace - formally typeset
I

Işık Adalet

Researcher at Istanbul University

Publications -  53
Citations -  1089

Işık Adalet is an academic researcher from Istanbul University. The author has contributed to research in topics: Scintigraphy & Hyperparathyroidism. The author has an hindex of 18, co-authored 53 publications receiving 970 citations. Previous affiliations of Işık Adalet include Freeman Hospital.

Papers
More filters
Journal ArticleDOI

Impact of gland morphology and concomitant thyroid nodules on preoperative localization of parathyroid adenomas.

TL;DR: The aim of this study was to assess the effect of the presence of thyroid nodules, adenoma weight, and ectopic localization on the sensitivity of different imaging studies in patients with hyperparathyroidism.
Journal ArticleDOI

Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients.

TL;DR: It is shown that hepatopulmonary syndrome may occur in both liver cirrhosis and noncirrhotic portal hypertension and that portal hypertension is the predominant etiopathogenic factor related to hepatopurmonary syndrome.
Journal ArticleDOI

Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation.

TL;DR: 68Ga-DOTATATE has high T/B ratio with physiological biodistribution comparable to its counterparts, however, the presence of SSTRs in benign and malignant lesions unrelated to NET may be challenging in interpretation particularly where the physiological uptake is variable.
Journal ArticleDOI

Can Complementary 68Ga-DOTATATE and 18F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?

TL;DR: Combined 68Ga-DOTATATE and 18F-FDG PET/CT is helpful in the individual therapeutic approach of GEPNETs and can overcome the shortcomings of histopathologic grading especially in intermediate-grade GEP NETs.
Journal ArticleDOI

The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.

TL;DR: FDG-PET/CT can accurately detect tumor recurrence in patients with suspected recurrent CRC, even for patients with normal CEA levels, according to retrospective evaluated the diagnostic performance.